reports
Davide Campari: 1 director
A director at Davide Campari sold 800,000 shares at 5.726EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Ipsen expands early development pipeline with Simcere Zaiming’s innova...
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugateSIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy dataProgram expected to enter Phase I clinical development in H2 2026Simcere Zaiming is eligible to receive up to $1.06B in total payments PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclus...
Ipsen élargit son portefeuille de produits en développement précoce av...
Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming Ipsen obtient les droits mondiaux exclusifs, en dehors de la Grande Chine, pour le développement, la fabrication et la commercialisation de SIM0613, un conjugué anticorps-médicament ciblant le récepteur LRRC15.SIM0613 est conçu de manière optimale pour une pénétration intra-tumorale supérieure, étayée par des données d’efficacité précliniques probantes.Le programme devrait entrer en Phase I de développement clinique au second semestre 2026. Simcere...
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone...
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are ...
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients a...
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP) PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation anormale de nouvelle matière osseuse (ossification hétérotopique ou OH) chez l’adulte et l’enfant atteints de fibrodysplasie ossifiante progressive (FOP), par rapport au placebo, en conséquence, l'étude sera clôturée. Le mé...
- Pierre Tegner
- Pierre Tegner
- Anthony Dick
- Marc Lavaud
- Michael Foundoukidis
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
APAML APERAM SA
VOLV B VOLVO AB CLASS B
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
RI PERNOD RICARD SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
KCO KLOECKNER & CO SE
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
JCQ JACQUET METALS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
VOW3 VOLKSWAGEN AG PREF
EZJ EASYJET PLC
CIE CIE AUTOMOTIVE S.A.
RACE FERRARI NV
PIRC PIRELLI & C. S.P.A.
STM STMICROELECTRONICS NV
GEST GESTAMP AUTOMOCION S.A.
8TRA TRATON SE
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
DTG DAIMLER TRUCK
IVG IVECO GROUP
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Anthony Dick
- Marc Lavaud
- Michael Foundoukidis
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
APAML APERAM SA
VOLV B VOLVO AB CLASS B
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
RI PERNOD RICARD SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
KCO KLOECKNER & CO SE
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
JCQ JACQUET METALS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
VOW3 VOLKSWAGEN AG PREF
EZJ EASYJET PLC
CIE CIE AUTOMOTIVE S.A.
RACE FERRARI NV
PIRC PIRELLI & C. S.P.A.
STM STMICROELECTRONICS NV
GEST GESTAMP AUTOMOCION S.A.
8TRA TRATON SE
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
DTG DAIMLER TRUCK
IVG IVECO GROUP
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Pierre Tegner
- Pierre Tegner
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi...
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des thérapies d’immuno-oncologie de nouvelle génération. A propos d’Ipsen Nous sommes un groupe biopharmaceutique mondial focalisé sur la mise au point de médicaments innovants pour les patients dans trois domaines thérapeutiques : l’Oncologie, les Maladies Rare...
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncolog...
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 year...
- Bruno Cavalier
- Charlotte Vaisse
- Jean Danjou
- Maxime Kogge
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
MF WENDEL SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SDF K+S AG
01913 PRADA S.P.A.
CARM CARMILA SAS
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
WINE PURCARI WINERIES PCL
ZGN ERMENEGILDO ZEGNA NV
- Bruno Cavalier
- Charlotte Vaisse
- Jean Danjou
- Maxime Kogge
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SAN SANOFI
01913 PRADA S.P.A.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
ZGN ERMENEGILDO ZEGNA NV
- Bruno Cavalier
- Charlotte Vaisse
- Jean Danjou
- Maxime Kogge
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
MF WENDEL SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SDF K+S AG
01913 PRADA S.P.A.
CARM CARMILA SAS
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
WINE PURCARI WINERIES PCL
ZGN ERMENEGILDO ZEGNA NV
- Bruno Cavalier
- Charlotte Vaisse
- Jean Danjou
- Maxime Kogge
MC LVMH MOET HENNESSY LOUIS VUITTON SE
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SAN SANOFI
01913 PRADA S.P.A.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
ZGN ERMENEGILDO ZEGNA NV
- Jean Danjou
- Jean Danjou
- Jean Danjou
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.